Skip to main content

Advertisement

Table 3 Significant association between TFPI single nucleotide polymorphisms (SNPs) and clinicopathological characteristics and molecular subtypes

From: Tumor expression, plasma levels and genetic polymorphisms of the coagulation inhibitor TFPI are associated with clinicopathological parameters and survival in breast cancer, in contrast to the coagulation initiator TF

Characteristic SNP Risk allele Odds ratio 95% CI P False discovery rate
T status       
T1    Reference Reference Reference Reference
T2 to T3 rs10153820 A 3.14 1.44, 6.86 0.004 0.056
TN status (ER-/PR-/HER2-negative)       
No    Reference Reference Reference Reference
Yes rs8176541a G 2.62 1.11, 5.35 0.026 0.092
  rs3213739a G 2.58 1.34, 4.99 0.005 0.033
  rs8176479a C 3.10 1.24, 7.72 0.015 0.071
  rs2192824a T 2.44 1.39, 4.93 0.002 0.033
N status       
Positive    Reference Reference Reference Reference
Negative rs10179730 G 3.34 1.42, 7.89 0.006 0.083
Basal tumor subtype       
Non-basal    Reference Reference Reference Reference
Basal rs3213739a G 2.23 1.15, 4.34 0.018 0.107
  rs8176479a C 2.79 1.12, 6.96 0.028 0.107
  rs2192824a T 2.41 1.24, 4.65 0.009 0.107
  rs10187622a C 5.20 1.17, 23.20 0.031 0.107
Luminal B tumor subtype       
Non-luminal B    Reference Reference Reference Reference
Luminal B rs16829086a T 2.09 1.03, 4.25 0.041 0.191
  rs10179730a G 3.53 1.47, 8.46 0.005 0.066
  rs10187622a T 2.73 1.24, 6.03 0.013 0.091
Normal-like tumor subtype       
Non-normal-like    Reference Reference Reference Reference
Normal-like rs5940 T 22.17 4.43, 110.8 0.0002 0.003
  1. aSNPs representing a haplotype effect. SNPs are listed by ascending chromosome positions. TFPI, tissue factor pathway inhibitor; ER, estrogen receptor; PR, progesterone receptor; HER2, human epidermal growth factor 2.